Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Inmune Bio, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 41 | 43 | +2 |
| Shares | 1.94M | 2.49M | +543.6K (+28.0%) |
| Value | $37.7M | $25.4M | −$12.4M (−32.8%) |
New holders (8)
Institutions that held Inmune Bio, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 24,364 | $249.0K | 0.03% |
| Jump Financial, LLC | 21,100 | $215.0K | 0.01% |
| Goldman Sachs Group Inc | 20,053 | $205.0K | 0.00% |
| Jane Street Group, LLC | 17,098 | $175.0K | 0.00% |
| Walleye Capital LLC | 17,127 | $175.0K | 0.01% |
| Westside Investment Management, Inc. | 7,800 | $79.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 7,306 | $75.0K | 0.00% |
| High Net Worth Advisory Group LLC | 500 | $5.00K | 0.00% |
Sold out (6)
Institutions that held Inmune Bio, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Ikarian Capital, LLC | 26,632 | $517.0K |
| DG Capital Management, LLC | 20,000 | $388.0K |
| Cubist Systematic Strategies, LLC | 19,989 | $388.0K |
| Belvedere Trading LLC | 16,177 | $302.0K |
| Kelly Financial Services LLC | 2,000 | $38.8K |
| Parallel Advisors, LLC | 100 | $2.00K |